Loading news...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hardman Johnston Global Advisors LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 26.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,152 shares of the pharmaceutical company's stock after selling 29,073 shares during the period. Vertex Pharmaceuticals comprises
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke.
Alphabet is playing to win in the AI market. Micron is arguably the biggest AI bargain around.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) EVP Ourania Tatsis sold 4,500 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the transaction, the executive vice president directly owned 42,293 shares
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-seven analysts that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating on
HB Wealth Management LLC reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 18.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,680 shares of the pharmaceutical company's stock after selling 1,903 shares during the period. HB Wealth
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $463.86, indicating a -1.24% shift from the previous trading day.
Duncker Streett and Co. Inc. lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 69.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,355 shares of the pharmaceutical company's stock after selling 5,377 shares during the period. Duncker Streett
Vertex Pharmaceuticals (VRTX) reached $469.68 at the closing of the latest trading day, reflecting a -2.99% change compared to its last close.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Cerity Partners LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 1.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 258,808 shares of the pharmaceutical company's stock after selling 4,884 shares during the quarter. Cerity Partners LLC owned approximately 0.10%
Galvin Gaustad and Stein LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 44.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,142 shares of the pharmaceutical company's stock after acquiring an additional 10,252 shares during the quarter.
This selection of stocks offers interesting buys throughout industries -- from tech to healthcare. Many of these players are trading at bargain levels.
Generali Asset Management SPA SGR lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 41.8% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,569 shares of the pharmaceutical company's stock after acquiring an additional 6,942 shares during the period. Generali Asset Management SPA
Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges.
Amazon's profitability underscores the success of established and emerging growth sources. Vertex Pharmaceuticals is launching several new products, and more approvals could be around the corner.